Market Research

Rubella Vaccine Market Growing at a CAGR of 6.07 During Forecast Period 2020-2025

rubella vaccine market growing at a cagr of 6 07 during forecast period 2020 2025

Sep 2, 2020 4:43 PM ET
4169 1599045432

iCrowd Newswire – Sep 2, 2020

Rubella Vaccine Market size is forecast to reach 4.3 billion by 2025, growing at a CAGR of 6.07 during the forecast period 2020-2025. Rubella is a contagious infection which  is caused  by the transmission of  airborne droplets of infected people through coughing or sneezing. Increase  in the incidence of rubella infection and increase in the infection which results in congenital defects known as congenital rubella syndrome are the major factors driving the growth of the market is set to further enhance the overall market demand of rubella vaccine  during the forecast period 2020-2025.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=502008

Report Price: $ 4500 (Single User License)

End User- Segment Analysis

Rubella is a severe and infectious disease triggered by a virus. Pediatric vaccines are given in two doses. First at the age of 15 months and second is before the age of six. Pediatric vaccines are more effective than adult vaccines. Adult vaccine is only single dose vaccine. Both vaccines contain small amounts of neomycin and gelatin. They are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Pediatric Vaccines is forecast to be the fastest growing with a CAGR of 7.15% during the forecast period 2020-2025. This is owing to the growing initiatives for immunization against diseases.

Application – Segment Analysis

Hospital Pharmacies dominates the rubella vaccine market owing to  growing industrialization which is leading to propel the airborne diseases globally and the symptoms related to airborne diseases include fever, cough, redness in the eyes and running nose coupled with rashes in the body. Increase in the success rate of vaccination schemes depends on government initiatives of each country. Rubella vaccine is also used in drug stores and retail pharmacies. Hospital pharmacies is set to be the fastest growing segment of the rubella vaccine market during the forecast period 2020-2025.

Geography – Segment Analysis

North America dominates  the rubella vaccine   market with a share of more than 37.1%, followed by Europe owing to the high awareness about the disease and vaccination ,Increasing government immunization programs and  manufactures supports to provide cost-effective vaccines  is driving the growth of the rubella vaccine market in the forecast period 2020-2025.

However, Europe is estimated to grow at a highest CAGR during the forecast period 2020-2025 owing to the increasing government vaccination programs and growing investments in vaccination. Increasing healthcare expenditure, government initiatives, increasing per capita income and the expansion of vaccination programs by the government to increase prevention from infectious disease is boosting the growth of the rubella vaccine market in Europe region

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=502008

Drivers – Rubella Vaccine Market

  • Increase in government focus on rubella vaccination

Increase in government focus on rubella vaccination is increasing the demand of the rubella vaccine market owing to the rising government and non-government funding for rubella vaccine development and the high prevalence of diseases. Increasing investment by companies, increasing global vaccination coverage and growing immunization programs is estimated to propel the growth of rubella vaccines market. Rubella can cause serious birth deficiencies in developing baby if a woman is infected when she is pregnant. The best method to protect against rubella and measles is measles-rubella (MR) vaccines which give long-term immunity and for this various government and organizations are conducting preventive programs.

  • Increase in the infection which results in congenital defects

Increase in the infection which results in congenital defects is increasing the demand of the rubella vaccine market owing to the increasing number of incidences and prevalence of the disease. The virus replicates in the respiratory tract and is transmitted to others via respiratory secretions through aerosolized droplets in closed areas and appearance of symptoms is 10-12 days after the infection which is usually fever. Rubella vaccine should not be given to the individuals who are on immunosuppressants as the virus can replicate and cause infections. There is no cure for congenital rubella syndrome, and it is important to prevent it and for the prevention of congenital defects MMR (measles, mumps, rubella) vaccine is given at least 28 days beforehand.

Challenges – Rubella Vaccine Market

  • Reactions related to vaccinations and insufficient yield   

Some of the factors that impede the growth of the rubella vaccine   market are reactions related to vaccinations and insufficient yield with high selectivity of human diploid cell while constructing rubella vaccines.

Acquisitions/Product Launches

  • In December 2019, Merck & Co. Inc, acquires ArQule which is famous for its targeted therapies.
  • In January 2019, GlaxoSmithKline Plc, acquires TESARO.

Key Takeaways

  • North America dominates the Rubella Vaccine Market owing to growing initiatives for immunization against diseases. The Rubella Vaccine Market scope for different regions will be provided in the final report.
  • Rising air pollution and increase in governments focus on rubella vaccination   is likely to aid in the market growth of rubella vaccine market
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Rubella Vaccine Market report.
  • Reactions related to vaccinations and insufficient yield is set to create hurdles for the Rubella Vaccine Market.

Rubella Vaccine Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Rubella Vaccine Market. In 2019, Rubella Vaccine Market share is consolidated by the top ten players present in the market. Rubella Vaccine top 10 companies are Merck & Co. Inc., GlaxoSmithKline Plc, Sanofi Aventis, Pfizer Inc., Blerna Biotech, Serum Institute of India, Astellas Pharma Inc., CSL Limited and Chiron Corporation, among others.

Related Reports:

Meningococcal Conjugate Vaccine Market

https://www.industryarc.com/Research/Meningococcal-Conjugate-Vaccine-Market-Research-502186

Pneumococcal Polysaccharide Vaccine Market

https://www.industryarc.com/Research/Pneumococcal-Polysaccharide-Vaccine-Market-Research-502189

About IndustryARC:

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

Contact Information:

Venkat Reddy
Sales Director
Email: [email protected]
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677


iCrowdNewswire

Keywords:    Rubella Vaccine Market,Rubella Vaccine Market size,Rubella Vaccine industry,Rubella Vaccine Market share, Rubella Vaccine Market report,Rubella Vaccine Market outlook

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *